RPID

Rapid Micro Biosystems (RPID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LEXINGTON, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its participation as a sponsor of the PDA Pharmaceutical Microbiology Conference 2026, taking place in Washington, D.C.

LEXINGTON, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced plans to participate in the following upcoming investor conferences:

Rapid Micro Biosystems (RPID) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

The heavy selling pressure might have exhausted for Rapid Micro Biosystems (RPID) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Rapid Micro Biosystems (RPID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Rapid Micro Biosystems, Inc. (RPID) Q2 2026 Earnings Call Transcript

Rapid Micro Biosystems NASDAQ: RPID reported second-quarter revenue of $8.1 million, up 11% from $7.3 million a year earlier and above the company's prior guidance, as consumable sales, service activity and recurring revenue increased.

Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.27 per share a year ago.

Reports  second quarter 2026 total revenue of $8.1 million , representing 11% growth compared to the second quarter of 2025 Achieved a significant milestone with the 200th Growth Direct system placed globally; placed four Growth Direct systems and completed nine validations in the second quarter 2026 Second quarter consumable revenue increased more than 20% year-over-year Second quarter recurring revenue increased 14% year-over-year; comprised 63% of total revenue Reports record second quarter total gross margin of 15% , an increase of 11 percentage points compared to the  second quarter of 2025 Merck MilliporeSigma to host European Growth Direct Day in October 2026, supporting customer engagement, education, and commercial pipeline development across Europe Reaffirms full year 2026 total revenue guidance range of $37.0 million to $41.0 million, including 30 to 38 Growth Direct system placements Reaffirms full year 2026 gross margin percentage guidance of approximately 20%, with second half 2026 margins in the mid-20% range LEXINGTON, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended June 30, 2026.